Inhalable formulations for treating pulmonary hypertension and methods of using same
CA 2530632 C · Owner: Merck Patent Gesellschaft Mit Beschraenkter Haftung · Inventors: Chaudry, Imtiaz
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g. humans) wherein the , formulation comprises at least one hypertension reducing agent including but , not limited to an angiotensin converting enzyme inhibitor angiotensin , receptor blocker, beta-blocker calcium-channel blocker or vasodilator or any , combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 18, 2004 and granted March 6, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 18, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 18, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.